Abstract:¹⁸F-FDG PET-CT has been widely used for the diagnosis, staging and assessment of therapeutic response in patients with non-small cell lung cancer (NSCLC). In particular, the technique plays an important role in the prediction of the response to therapy in patients with locally advanced NSCLC. It can dynamically observe the tumor tissue metabolism, and according to the changes of¹⁸F-FDG uptake by visual or quantitative analysis, before and after treatment, allow prediction of the early efficacy of locally advanced NSCLC with chemotherapy and (or) radiotherapy in clinical or sub-clinical levels.